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Background: The majority of patients with chondrosarcoma of bone have an excellent overall survival after local
therapy. However, in case of unresectable locally advanced or metastatic disease the outcome is poor and limited
treatment options exist. Therefore we conducted a survey of clinical phase I or II trials and retrospective studies that
described systemic therapy for chondrosarcoma patients.
Materials and methods: Using PubMed, clinicaltrials.gov, the Cochrane controlled trial register and American
Society of Clinical Oncology (ASCO) abstracts a literature survey was conducted. From the identified items, data
were collected by a systematic analysis. We limited our search to semi-recent studies published between 2000 and
2013 to include modern drugs, imaging techniques and disease evaluations.
Results: A total of 31 studies were found which met the criteria: 9 phase I trials, 11 phase II and 8 retrospective
studies. In these studies 855 chondrosarcoma patients were reported. The tested drugs were mostly non-cytotoxic,
either alone or in combination with another non-cytotoxic agent or chemotherapy. Currently two phase I trials, one
phase IB/II trial and three phase II trials are enrolling chondrosarcoma patients.
Conclusion: Because chondrosarcoma of bone is an orphan disease it is difficult to conduct clinical trials. The
meagre outcome data for locally advanced or metastatic patients indicate that new treatment options are needed.
For the phase I trials it is difficult to draw conclusions because of the low numbers of chondrosarcoma patients
enrolled, and at different dose levels. Some phase II trials show promising results which support further research.
Retrospective studies are encouraged as they could add to the limited data available. Efforts to increase the
number of studies for this orphan disease are urgently needed.
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Chondrosarcoma (CS) is the second most common pri-
mary bone sarcoma in humans, but with an estimated
incidence of 0.2 in 100.000 patients per year it is still a
very rare disease [1]. CS mostly affects adults between
the age of 20 and 60 [2]. CS belong to a very diverse
group of tumors having in common the production of
cartilaginous matrix. Almost 90% of the CS are of the
conventional subtype, but there are also the more rare
subtypes with their own distinct histological and clinical* Correspondence: a.j.gelderblom@lumc.nl
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article, unless otherwise stated.features including clear cell, mesenchymal and dediffer-
entiated CS [3]. The prognosis for patients with CS is
very diverse with a very good prognosis for atypical car-
tilaginous tumour/CS grade I which are slow growing
and do not metastasize and a poor prognosis for grade
III CS which have a high risk, up to 70%, for local recur-
rence and metastasis [4,5]. Currently the most com-
monly used treatment option for atypical cartilaginous
tumour/CS grade I is curettage with local adjuvants
which is usually enough to cure the patient. However,
for grade II and grade III CS en bloc resection is re-
quired. If a patient has unresectable or metastasized dis-
ease the current treatment options are very limited. CS
has always been considered to be chemotherapy andCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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would not benefit from non-surgical treatment. However,
new preclinical work and retrospective studies show that
there may be a place for non-cytotoxic, chemo- and radio-
therapy in the treatment of CS [6,7]. In the last decades
more knowledge has become available about the molecu-
lar background of the different CS subtypes (for review
see [8-10]). Investigators have been trying to find new sys-
temic treatment options for these patients through phase I
and II clinical trials (no phase III studies were ever con-
ducted). Because CS is such a rare disease, and high grade
metastatic or unresectable disease is even more uncom-
mon, the number of patients in these trials is however low
and thereby it is difficult to give a clear answer to the
question whether a new drug improves outcome or not.
Here we report an overview of a survey we conducted on
published and presented phase I and II clinical trials and
retrospective studies on systemic therapy enrolling CS pa-
tients, published from 2000 until 2013. We also include
the studies that are enrolling patients at this moment.
Material and methods
Search strategy
To collect phase I and II and retrospective studies which
included CS patients we used the search machines
PubMed, clinicaltrials.gov, the Cochrane controlled trial
register and American Society of Clinical Oncology
(ASCO) abstracts. For the search criteria we used the
terms [chondrosarcoma] AND [phase I OR phase II OR
retrospective] AND [clinical trial]. To check for missed
articles we widened the search to [sarcoma] AND [phase
I OR phase II] AND [clinical trial] and compared the re-
sults. When multiple reports from the same trial were
published we only used the article with the longest fol-
low up time. Publications were used if they 1) described
results from an early phase clinical trial in which CS pa-
tients were included, either prospective or retrospective,
2) were written in English. The latest search was per-
formed in December 2013. Studies on extraskeletal myx-
oid CS were excluded.
Data were collected from trials published between
2000 and 2013 to include modern drugs, imaging tech-
niques and disease evaluations. Data extraction was done
by one of the authors (A.v.M) and a systemic analysis
was applied that is normally used for meta-analysis [11].
From all reports author name, year of publication, num-
ber of patients, intervention and outcome data were
noted.
Results
From 2000 until 2013 a total of 31 phase I, II or retro-
spective clinical trials were reported that enrolled 1 or
more CS patients: 11 phase I, 11 phase II and 8 retro-
spective studies. Figure 1 shows a flow-chart indicatingthe search method for clinical trials included in this ana-
lysis. Figure 2 shows a timetable with the number and
type of clinical trials that met our criteria and their time
of publication showing an increasing number of publica-
tions from 2004 onwards. The data from the trials that
were included in this study are shown in Table 1 for the
phase I trials, Table 2 for phase II trials and Table 3 for
the results of the retrospective studies. In the clinical tri-
als that were identified a total of 1927 patients were in-
cluded of which 855 are patients with CS. Histological
subtypes included were conventional, dedifferentiated
and mesenchymal. The actual number of patients with
CS may be higher because in some of the phase I trials
only the CS patients who had an objective response or
stable disease were reported but more may have been
enrolled. The drugs that were being tested were mostly
non-cytotoxic in the phase I trials, either alone or in
combination with another non-cytotoxic agent or con-
ventional chemotherapy in the phase II trials. For the
retrospective studies all treatments were conventional
chemotherapy based. In the phase I trials of the 13 in-
cluded CS patients there were no complete response
(CR), 2 (15%) partial response (PR) and 7 (54%) stable
disease (SD). For the phase II trials 156 CS patients were
enrolled with 2 (1.3%) CR, 2 (1.3%) PR and 21 (13.4%)
SD. The results on the clinicaltrials.gov website for
current trials are shown in Table 4. Two phase I trials,
one phase IB/II trial and three phase II trials were found.
There are no phase III trials that are currently or were
ever recruiting CS patients.
Discussion
CS is a primary bone cancer that in most patients can
be cured by local treatment alone. When tumors are
unresectable, either because of locally advanced or meta-
static disease, systemic treatment options are very lim-
ited due to the current view that non-surgical treatment
options have no benefit. Currently for advanced CS pa-
tients the outcome is poor with an overall survival of
less than two years [5,40,41].
The general insensitivity to chemotherapy in CS may be
due to activation of anti-apoptotic and pro-survival path-
ways and therefore future treatment of advanced CS pa-
tients could benefit from targeted agents that specifically
interfere with these pathways, rendering the tumours
more sensitive to the conventional chemotherapeutic
agents [8,9,40]. For instance, the anti-apoptotic proteins
Bcl-2 and Bcl-XL are highly expressed in all CS subtypes
and the BH-3 mimetic ABT-737 renders CS cell lines sen-
sitive to the conventional chemotherapeutic agents doxo-
rubicin and cisplatin [10,40]. Survivin, a member of the
inhibitor of apoptosis protein family, is expressed in CS
samples and RNA interference targeted on survivin results
in cell cycle arrest and increased apoptotic rates in CS cell






70 Reports excluded on the basis of 
abstract, title or no results published
36 Reports retrieved in full
text
6 Reports excluded on the basisof full 
text search
30Reports included in the 
analysis
Figure 1 Flow-chart showing the search method to identify the relevant clinical reports for our analysis.
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some novel approaches never make it to a clinical trial.
An example of this is the combination treatment of the
Bcl-2 inhibitor ABT-737 and doxorubicin. Drug compan-
ies were not interested to supply drug for a clinical trial so
it remains unclear if this combination is beneficial to pa-
tient outcome.Figure 2 Overview of the number of clinical trials included in the ana
blue, phase II trials in red and the retrospective trials in green.Two recent retrospective studies as well as animal
studies suggested that a subgroup of the patients may
benefit from non-cytotoxic agents, chemotherapy, radio-
therapy or a combination [6,7,41]. In systemic treatment,
being either a doxorubicin-containing chemotherapy regi-
men or non-cytotoxic drugs as imatinib and sirolimus, sig-
nificantly improved survival compared to no treatment inlysis according to the year of publication with phase I trials in
Table 1 Phase I trials included in the analysis showing the name of the author, year of publication, number of patients
enrolled in the trial, the intervention that was tested and the outcome
Author Year No of patients Intervention Outcome for CS patients
Serrone et al. [12] 2001 44 advanced sarcoma (2 CS) Group A: IFOS short infusion + EPI Not mentioned
Group B: IFOS continuous infusion + EPI
Schwartz et al. [13] 2005 38 advanced solid tumors with 6 sarcoma




Levine et al. [14] 2006 51 advanced malignancies with 7 sarcoma
with at least 1 CS
Veglin (VEGF antisense oligodeoxynucleotide) 1 SD
Lockhart et al. [15] 2007 18 advanced malignancies (1 CS) MAC-321 (analogue of docetaxel) 1 SD
Chawla et al. [16] 2009 20 advanced sarcoma (1 CS) Rexin-G (tumor-targeted retrovector) Not mentioned
Group A: 2 times a week
Group B: 3 times a week
Camidge et al. [17] 2010 50 advanced malignancies with 11 sarcoma
with at least 1 CS
PRO95780 (death receptor 5 antibody) 1 SD
Herbst et al. [18] 2010 71 advanced malignancies with 9 sarcoma
with at least 2 CS
rhApo2L/TRAIL (death receptor activator) 2 PR
Cohort 1: dose escalation
Cohort 2: treated at MTD
Olmos et al. [19] 2010 29 advanced sarcoma (1 CS) Figitumumab (IGF1R antibody) 1 SD
Qeuk et al. [20] 2010 21 advanced solid tumors (1 CS) Everolimus (mTOR inhibitor) and figitumumab
(IGF1R antibody)
1 SD
Stroppa et al. [21] 2010 8 advanced sarcoma (1 CS) Doxorubicin + IFOS Not mentioned
Pacey et al. [22] 2011 25 advanced solid tumors with at least 1 CS Alvespimycin (heat shock protein 90 inhibitor) 1 SD
CS chondrosarcoma, EPI epirubicin, IFOS ifosfamide, PR partial response, SD stable disease.
Table 2 Phase II trials included in the analysis with the name of the author, year of publication, number of patients
enrolled in the trial, the intervention that was tested and the outcome
Author Year No of patients Intervention Outcome for CS
patients
Merimsky et al. [23] 2000 18 advanced sarcoma (3 CS) Gemcitabine 2 SD
Skubitz et al. [24] 2003 47 advanced sarcoma (1 CS) Pegylated-liposomal doxorubicin Not mentioned
Nooij et al. [25] 2005 37 bone sarcoma (16 CS) Doxorubicin + cisplatin 2 CR
Group A: operable, non-metastatic (4 CS) 3 SD
Group B: inoperable, metastatic (12 CS)
Maki et al. [26] 2009 145 advanced sarcoma (2 CS) Sorafenib (multi-tyrosine kinase inhibitor) Not mentioned
Pacey et al. [27] 2009 26 advanced sarcoma (2 CS) Sorafenib(multi-tyrosine kinase inhibitor) 1 SD
Grignani et al. [28] 2011 26 advanced chondrosarcoma Imatinib mesylate (c-kit/PDGFR inhibitor) 8 SD
OS 11 months
Fox et al. [29] 2012 53 advanced sarcoma (25 CS) Gemcitabine + docetaxel 2 PR
Italiano et al. [30] 2012 40 advanced CS GDC-0449/vismodegib (hedgehog inhibitor) 4 SD (of first 17 patients)
Schuetze et al. [31] 2012 49 advanced sarcoma (2 CS) Sirolimus (mTOR inhibitor) + cyclophosphamide 1 SD
Ha et al. [32] 2013 36 advanced sarcoma Cetuximab (EGFR antibody) PD
Group A: EGFR+
Group B: EGFR- (1 CS)
Schwartz et al. [33] 2013 388 advanced sarcoma Cixutumumab (IGF1R antibody) + temsirolimus
(mTOR-inhibitor)
Not mentioned
Group A: IGF-1R + soft tissue sarcoma
Group B: IGF-1R + bone sarcoma (20 CS)
Group C: IGF-1R- sarcoma (18 CS)
CR complete response, CS chondrosarcoma, OS overall survival, PD progressive disease, PFS progression free survival, PR partial response, SD stable disease.
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Table 3 Retrospective trials included in the analysis showing the name of the author, year of publication, number of
patients enrolled in the trial, the intervention that was tested and the outcome
First author Year of
publication
No of patients Intervention and number of patients Outcome of systemic therapy
Mitchell [34] 2000 22 resectable dediff CS Doxorubicin based chemotherapy +
surgery
1/5 > 90% necrosis after preoperative
chemo
5 preoperative chemotherapy and 6
postoperative, 11 no chemotherapy
5 year OS with chemotherapy 36%,
without 0%
Dickey [35] 2004 42 local or advanced
dediff CS
15 Surgery 5 year OS and median OS: with surgery
11.8% and 6.4 months
22 surgery and chemotherapy 5 other
With surgery and chemotherapy 4% and
8.4 months
Staals [36] 2006 102 local or advanced
dediff central CS
68 Surgery Median survival 18 vs 23 months
(not significant)
25 surgery + chemotherapy
9 palliative care
Cesari [7] 2007 24 local or advanced
mesenchymal CS
24 surgery of which: 10 year OS:
5 + RT Surgical remission 27%
12 + chemotherapy Non-surgical remission 0%
Complete surgical remission 10 year DFS:
With chemotherapy 76%, without 17%
Grimer [37] 2008 266 local and 71
advanced dediff CS
207 Surgery Local disease
90 chemotherapy 5 year OS:
40 surgery + chemotherapy With chemotherapy 33%, without 25%
(p = 0.11)
Advanced disease
Median OS: With chemotherapy 7 months,
without 3 months (not significant)
Dantonello [38] 2008 14 local mesenchymal CS 12 Surgery + chemotherapy 10 year OS 64%
2 surgery + RT
Bernstein-Molho [39] 2012 9 advanced CS Sirolimus + cyclophosphamide OR 11%
SD 56%
PFS 15 months




CS chondrosarcoma, Dediff dedifferentiated, DFS disease free survival, OR objective response, OS overall survival, PFS progression free survival, RT radiotherapy,
SD stable disease.
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[41]. For patients with only locally advanced disease radio-
therapy may be a good therapeutic option with a signifi-
cant survival benefit compared to no treatment. Patients
with mesenchymal or dedifferentiated CS may also benefit
from systemic treatment [6], and further clinical studies
are warranted looking at specific CS subtypes.
Recently also new treatment options were tested in
clinical trials such as the hedgehog (Hh) inhibitor IPI-
926. Hedgehog signaling was previously shown to be im-
portant in CS genesis [43-45]. CS xenograft models were
treated with IPI-926 and showed a downregulation of
the Hh pathway in the tumors and a significant growthinhibition in both newly planted as well as established
CS tumours with a mean of 43% [30]. Because of the
strong preclinical results a randomized phase II trial
studying the effect of IPI-926 compared to placebo in
metastatic or locally advanced CS patients was con-
ducted (NCT01310816). The study showed that IPI-926
is well tolerated but there was no difference in PFS or
OS compared to placebo. However a small subset of pa-
tients had minor reductions in tumour size. Another Hh
inhibitor that was tested in a phase II trial including ad-
vanced CS patients was GDC-0449, also called vismode-
gib (NCT01267955). This study did not meet its primary
endpoint, but the results suggested activity of the drug
Table 4 Overview of the trials currently recruiting chondrosarcoma patients, showing the clinicaltrials.gov number,
title of the study and the phase
Clinicaltrials.gov number Title Phase
NCT01522820 Vaccine therapy with or without sirolimus in treating patients with NY-ESO-1 expressing solid tumors I
NCT01643278 Dasatinib and ipilimumab in treating patients with gastrointestinal stromal tumors or other sarcomas that
cannot be removed by surgery or are metastatic
I
NCT01154452 Vismodegib and gamma-secretase/notch signalling pathway inhibitor RO4929097 in treating patients with
advanced or metastatic sarcoma
IB/II
NCT01330966 Study of pazopanib in the treatment of surgically unresectable or metastatic chondrosarcoma II
NCT00928525 Imatinib in patients with desmoid tumor and chondrosarcoma II
NCT01653028 Alisertib in treating patients with advanced or metastatic sarcoma II
Not yet assigned A phase 2, single arm, multi center trial evaluating the efficacy of the combination of sirolimus and
cyclophosphamide in metastatic or unresectable myxoid liposarcoma and chondrosarcoma.
II
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ventional CS [46]. Despite the fact that in both studies
only a small subset showed benefit, it is important to do
these trials even if the results do not seem promising for
the whole patient group. By studying the tumor tissue of
the small subset of responders, we may learn to better
understand the mode of action. Moreover, this will en-
able the identification of biomarkers to predict which
patients do respond to the treatment to improve patient
selection in future trials.
According to the clinicaltrials.gov website currently 6
clinical phase I or II trials are enrolling CS patients, in
all of these trials non-cytotoxic agents are being tested
either alone or in combination. These treatments are
based on preclinical work that has been conducted over
the last years and which shows promising results. An ex-
ample of this is the mTOR pathway. Dysregulation of
mTOR signaling can be found in many tumor types,
however in clinical trials inhibitors of mTOR so far show
only modest results, which may be due to activation of
the PI3K/Akt pathway. In CS, both mTOR and AKT
were shown to be activated [28,42]. Dual inhibition using
BEZ235 dramatically decreased growth of CS cell lines
and xenografts [28]. The euroSARC consortium, www.
eurosarc.eu, is starting a phase II study in unresectable
conventional, dedifferentiated and mesenchymal CS with
the combination of sirolimus and cyclofosfamide. An ex-
ploratory analysis of the mTOR pathway is foreseen in
this study with pharmacokinetic assays on tumour biop-
sies taken before and after treatment (www.eurosarc.eu).
We conducted a search for all clinical phase I or II tri-
als and retrospective studies that included CS patients.
Because we intended to include modern imaging and
study designs the survey was limited to the period from
2000 until 2013. The list of the phase I trials that met
our search criteria is probably not completely reflecting
the actual number of CS patients enrolled in phase I clin-
ical trials, which is caused by the search strategy by which
trials that included CS patients without mentioning themin the abstracts are very difficult to find. Some of the
phase I trials could be found by using the Cochrane Con-
trolled Trial Register or the clinicaltrials.gov database, al-
though not all trials are registered in these databases. In
the phase I trials, with an average of 34 recruited patients,
only a small number of CS patients were enrolled at vari-
ous dose levels which make it difficult to conclude on the
effect of these new treatment options specifically for CS
patients. For the phase II trials sarcoma patients were en-
rolled in different strata. Some strata included CS patients
while the studies by Grignani and Italiano were restricted
to CS patients only [46,47].
For the retrospective studies it was difficult to make
definite conclusions on the effect of systemic therapy be-
cause many different chemotherapy treatment regimens
were used in patients with different stages of disease and
different CS subtypes. As the biological behavior of the
subtypes differs much with therefore expected different
outcomes it is hard to conclude from studies where the
specific subtype is not reported. The study by Cesari
[48] is very interesting because it shows that mesenchy-
mal CS patients who had a complete surgical remission
may benefit from adjuvant chemotherapy with a 10 year
disease free survival that improves from 10% without
chemotherapy to 76% with chemotherapy. This is in line
with previous studies and the current opinion is that
mesenchymal CS is a chemotherapy sensitive tumor
and that patients therefore benefit from chemotherapy
treatment [25,29]. For the other CS subtypes it has
generally been thought that they are insensitive to con-
ventional chemotherapy, although for dedifferentiated
CS activity was shown in individual cases and it is still
undefined if chemotherapy treatment is effective [3,12,49].
A retrospective study with 337 dedifferentiated CS
patients shows that the prognosis remains dismal,
however an improvement of survival, not significant,
in patients receiving chemotherapy who are under
60 years of age and had limb salvage treatment was
found [13]. Also for conventional CS more evidence is
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vival [41].
In conclusion, CS is a difficult patient population to
study in clinical trials. It is a very rare disease and most
patients can be cured by surgery alone, which makes the
group of patients that might need adjuvant or palliative
treatment even smaller. This is also one of the reasons
why it is very difficult to receive funding for these stud-
ies. However, from the current poor prognosis of non-
resectable locally advanced or metastatic CS patients it
is very clear that there is an unmet medical need and
new treatment options are warranted. To improve the
number of new treatment options for these patients it is
essential to collaborate and share data on research so
that future clinical trials have a sound biological ration-
ale and can be conducted with as few patients as pos-
sible in a short timeframe.
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